Ribeirao, Brazil: The administration of cannabidiol reduces anxiety in healthy subjects, according to placebo-controlled clinical trial data published in The Brazilian Journal of Psychiatry.
Investigators from the University of Sao Paulo in Brazil and Hebrew University in Israel compared the efficacy of varying doses of CBD versus placebo in a cohort of 57 participants performing a simulated public speaking test.
Authors reported that the administration of 300mg of CBD significantly reduced anxiety compared to placebo. By contrast, higher (600mg) and lower (150mg) of CBD provided little therapeutic benefit.
“Our findings confirm the anxiolytic-like properties of CBD and are consonant with results of animal studies describing bell-shaped dose-response curves,” they concluded. “Optimal therapeutic doses of CBD should be rigorously determined so that research findings can be adequately translated into clinical practice.”
For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test,” appears in The Brazilian Journal of Psychiatry.